ArticleJTO clinical and research reports2023

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.

Marcelo V Negrao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.